Curtis Florence1, Feijun Luo2, Ketra Rice2. 1. Division of Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: gul4@cdc.gov. 2. Division of Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
BACKGROUND: The United States (U.S.) is experiencing an ongoing opioid crisis. Economic burden estimates that describe the impact of the crisis are needed when considering federal and state resources devoted to addressing overdoses. In this study, we estimate the societal costs for opioid use disorder and fatal overdose from all opioids in 2017. METHODS: We estimated costs of fatal overdose from all opioids and opioid use disorder based on the incidence of overdose deaths and the prevalence of past-year opioid use disorder for 2017. Incidence of fatal opioid overdose was obtained from the National Vital Statistics System; prevalence of past-year opioid use disorder was estimated from the National Survey of Drug Use and Health. Costs were estimated for health care, criminal justice and lost productivity. Costs for the reduced quality of life for opioid use disorder and life lost due to fatal opioid overdose were valued using U.S. Department of Health and Human Services guidelines for valuing reductions in morbidity and mortality. RESULTS: Costs for opioid use disorder and fatal opioid overdose in 2017 were estimated to be $1.02 trillion. The majority of the economic burden is due to reduced quality of life from opioid use disorder and the value of life lost due to fatal opioid overdose. CONCLUSIONS: These estimates can assist decision makers in understanding the magnitude of opioid use disorder and fatal overdose. Knowing the magnitude and distribution of the economic burden can inform public policy, clinical practice, research, and prevention and response activities.
BACKGROUND: The United States (U.S.) is experiencing an ongoing opioid crisis. Economic burden estimates that describe the impact of the crisis are needed when considering federal and state resources devoted to addressing overdoses. In this study, we estimate the societal costs for opioid use disorder and fatal overdose from all opioids in 2017. METHODS: We estimated costs of fatal overdose from all opioids and opioid use disorder based on the incidence of overdose deaths and the prevalence of past-year opioid use disorder for 2017. Incidence of fatal opioid overdose was obtained from the National Vital Statistics System; prevalence of past-year opioid use disorder was estimated from the National Survey of Drug Use and Health. Costs were estimated for health care, criminal justice and lost productivity. Costs for the reduced quality of life for opioid use disorder and life lost due to fatal opioid overdose were valued using U.S. Department of Health and Human Services guidelines for valuing reductions in morbidity and mortality. RESULTS: Costs for opioid use disorder and fatal opioid overdose in 2017 were estimated to be $1.02 trillion. The majority of the economic burden is due to reduced quality of life from opioid use disorder and the value of life lost due to fatal opioid overdose. CONCLUSIONS: These estimates can assist decision makers in understanding the magnitude of opioid use disorder and fatal overdose. Knowing the magnitude and distribution of the economic burden can inform public policy, clinical practice, research, and prevention and response activities.
Authors: Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz Journal: Am J Public Health Date: 2015-06-11 Impact factor: 9.308
Authors: M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor Journal: Health Technol Assess Date: 2007-03 Impact factor: 4.014
Authors: Joshua A Barocas; Laura F White; Jianing Wang; Alexander Y Walley; Marc R LaRochelle; Dana Bernson; Thomas Land; Jake R Morgan; Jeffrey H Samet; Benjamin P Linas Journal: Am J Public Health Date: 2018-10-25 Impact factor: 11.561
Authors: Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt Journal: Neurosci Biobehav Rev Date: 2021-10-29 Impact factor: 8.989
Authors: Sigal Maya; James G Kahn; Tracy K Lin; Laurie M Jacobs; Laura A Schmidt; William B Burrough; Rezvaneh Ghasemzadeh; Leyla Mousli; Matthew Allan; Maya Donovan; Erin Barker; Hacsi Horvath; Joanne Spetz; Claire D Brindis; Mohsen Malekinejad Journal: PLoS One Date: 2022-07-18 Impact factor: 3.752
Authors: Cara A Struble; Kathryn Thomas; Madeline R Stenersen; Kelly E Moore; Catherine Burke; Brian Pittman; Sherry A McKee Journal: Am J Addict Date: 2022-03-03
Authors: Nikolai Jaschke; Sophie Pählig; Ying-Xian Pan; Lorenz C Hofbauer; Andy Göbel; Tilman D Rachner Journal: Trends Endocrinol Metab Date: 2021-03-03 Impact factor: 12.015
Authors: Mai ElSherief; Steven A Sumner; Christopher M Jones; Royal K Law; Akadia Kacha-Ochana; Lyna Shieber; LeShaundra Cordier; Kelly Holton; Munmun De Choudhury Journal: J Med Internet Res Date: 2021-12-22 Impact factor: 5.428